academic.oup.com
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Abstract. Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, af
#GLP-1 is an active hashtag on Bluesky. In the last 30 days, 20 people shared 61 posts with it — around 2 a day. Activity is down 17% versus the previous week, peaking on Sep 1 with 6 posts.
Tags most often used together with #GLP-1.
academic.oup.com
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Abstract. Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, af
www.biorxiv.org
Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats
Rationale: Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, are increasingly utilized in clinical practice due to their efficacy in promoting sustained weight loss following chr...
www.who.int
The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic®, ...
Excited to share our new GLP-1 receptor agonist study! Chronic semaglutide potentiates motivation for small food rewards and associated cues, but reduces intake when food is freely available—surprising twist! #GLP-1, #behavior #neuroscience #pharmacology 1/ 🔗 www.biorxiv.org/cgi/content/...
www.biorxiv.org
docwirenews.com
FDA Approves Ozempic for Kidney Disease | Docwire News
Based on FLOW trial results, the FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
www.kcci.com
Some GLP-1 companies facing lawsuits over vision loss. What to know
Some of the companies that produce GLP-1 drugs like Ozempic and Zepbound are facing lawsuits alleging that the drugs caused vision loss. Here's what to know.
www.who.int
The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic®, ...
buff.ly
Children taking GLP-1s can be at risk of nutritional deficiencies, study finds
Around one in six children taking glucagon-like peptide-1 receptor agonists (GLP-1s) experiences a nutritional deficiency within the first year of treatment, according to the results of a US study.…
www.thelancet.com
The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis
In this nationwide study, GLP-1RA were associated with reduced stroke risk, while SGLT2i and DPP-4i showed neutral effects. The overall direction of findings was consistent with evidence from RCT meta...
third-news.com
NBC Nightly News Highlights Naomi Wirth's Story and GLP-1 Medication Risks
Parker Waichman LLP commends NBC Nightly News, spotlighting Diane Wirth's vision loss story linked to GLP-1 drugs and legal actions ahead.
www.thelancet.com
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
Incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1–GIP receptor agonists, have transformed obesity management, producing substantial weight loss and cardiometabolic benefits, w...
fortune.com
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine | Fortune
Pattern hair loss affects an estimated 50 million men and 30 million women in the US, but there have been no new approved drugs since the late 1990s.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.